Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Werner Enterprises

Bayer AG (BAYZF) CEO Werner Baumann on Q4 2020 Results - Earnings Call Transcript

Bayer (BAYRY) reports in-line earnings and misses sales estimates in the fourth quarter of 2020.

Bayer's (BAYRY) Q4 Earnings Match Estimates, Sales Miss

DALLAS, Feb. 24, 2021 /PRNewswire/ -- Bayer, the maker of Roundup weedkiller, had hoped a proposed multibillion-dollar partial settlement with cancer victims would end its massive legal exposure to pending claims over the herbicide. However, efforts by Bayer (OTC: BAYRY) to resolve...

Bayer's Exposure to Thousands of Cancer Lawsuits Persists as Victims' Lawyers Vow to Continue the Fight

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that new NUBEQA® (darolutamide) and Xofigo® (radium Ra 223 dichloride) data will be presented at the 2021 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place from February 11-13, 2021. Among featured presentations are additional Phase III ARAMIS trial analyses evaluating the crossover effect from placebo to NUBEQA and safety follow-up in men with non-metastatic castration-resistant prostate cancer (

Bayer to Present Data that Reinforce Established Prostate Cancer Portfolio at 2021 ASCO GU Cancers Symposium

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and Orion Corporation are expanding the global clinical development program for the oral androgen receptor inhibitor (ARi) NUBEQA® (darolutamide) in prostate cancer. A new Phase III study ARANOTE will investigate NUBEQA in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone-sensitive prostate cancer (mHSPC). The study builds on the robust development program comprising multiple studies, including the Phase

Bayer and Orion Expand Development Program for NUBEQA® (darolutamide) in Prostate Cancer

Bayer AG struck a $2 billion deal to resolve future legal claims that its widely used weedkiller Roundup causes cancer, the German company said on Wednesday.

Bayer reaches $2 billion deal over future Roundup cancer claims

LEVERKUSEN, Germany--(BUSINESS WIRE)--Bayer announced today a formal agreement with plaintiffs' class counsel on a class plan designed to manage and resolve future Roundup™ cases. Plaintiffs' class counsel are filing today a motion for preliminary approval of the class agreement with Judge Vince Chhabria of the U.S. District Court for the Northern District of California, who presides over the Monsanto Roundup™ multi-district litigation. As part of the agreement, the company would be committed t

Bayer announces agreement with plaintiffs' counsel on class plan

BASEL, Switzerland--(BUSINESS WIRE)--As a part of the company's vision of “Health for All, Hunger for None,” Bayer is launching “The Nutrient Gap Initiative” which expands access to vitamins and minerals for underserved communities to help combat malnutrition. The program's goal is to reach 50 million people in underserved communities per year by 2030 through direct action and in partnership with critical non-governmental organizations (NGOs) with a focus on intervention, education, and advocac

Bayer Launches The Nutrient Gap Initiative to Expand Access to Vitamins and Minerals for 50 Million People Annually Worldwide by 2030

WHIPPANY, N.J.--(BUSINESS WIRE)--For the fourth consecutive year, Bayer U.S. obtained a perfect score of 100 percent on the 2021 Corporate Equality Index (CEI). Managed by the Human Rights Campaign (HRC), the CEI is a leading benchmarking report that measures and accounts for the corporate procedures relating to LGBTQ workplace equality. “It is such an honor to be recognized for our Inclusion & Diversity efforts by the Human Rights Campaign,” said Patrick Lockwood-Taylor, President of Bayer

Bayer Continues to Earn Top Marks in 2021 Corporate Equality Index

READING, England--(BUSINESS WIRE)--Bayer has received approval for the use of its oral Factor Xa inhibitor Xarelto®▼ (rivaroxaban) to treat VTE and to prevent VTE recurrence in children from birth to below 18 years after at least 5 days of initial parenteral anticoagulation treatment, including catheter related thrombosis, cerebral vein and sinus thrombosis.1 The use of a new formulation and strength granules for oral suspension 1mg/ml was also approved.1 Rivaroxaban is the first oral Factor Xa

Bayer Receives Approval in the UK for Xarelto®▼ (rivaroxaban) to Treat Children With Venous Thromboembolism (VTE) and to Prevent VTE Recurrence

Bayer (BAYRY) gets a boost as it wins approvals for a few candidates and enters into collaboration agreements.

Bayer (BAYRY) Gets a Boost With Product Approvals and Deals

Two law firms are suing Bayer for damages on behalf of shareholders, claiming the German group's management should have warned of the risk of lawsuits over the Roundup weedkiller when Bayer acquired Roundup maker Monsanto.

Investors sue Bayer over stock's slump in wake of Roundup litigation

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) and granted Priority Review for finerenone, an investigational drug for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This regulatory submission was based on Phase III FIDELIO-DKD trial data, which were recently presented at the American Society of Nephrology's (ASN) Kidney Week Reimagined 2020, and simultaneously published i

Bayer Announces U.S. FDA Accepts New Drug Application and Grants Priority Review for Investigational Drug Finerenone for Patients with Chronic Kidney Disease and Type 2 Diabetes

CureVac B.V

CureVac (CVAC) gains on a collaboration agreement with Bayer (BAYRY) for further development and supply of its COVID-19 vaccine candidate, CVnCoV.

CureVac (CVAC) Up on Deal With Bayer for COVID-19 Vaccine

CureVac stock popped in bullish volume Thursday after the company inked a collaboration deal with Bayer for its coronavirus vaccine. They hope to supply millions of doses worldwide.

This Covid Vaccine Stock Just Rocketed On A Deal With Pharma Giant Bayer

Sometimes you need a little help from a big brother.

CureVac Secures Bayer as a Partner for Its Coronavirus Vaccine

CureVac BV (NASDAQ: CVAC) shares have received a nice lift and breached the $100 level for the first time in the new year. What Happened: German coronavirus vaccine maker CureVac said Thursday it has signed a collaboration and services agreement with German chemicals company Bayer AG (Pink: BAYRY) for the further development, supply and territorial operations of CureVac's CVnCoV.

CureVac Shares Rip Higher On Coronavirus Vaccine Deal With Bayer

The shares of CureVac BV (NASDAQ:CVAC) are soaring this morning, up 18.5% at $102.88 at last check.

CVAC Soars on Bayer COVID-19 Vaccine Collaboration

The German biotech struck a deal with chemicals-and-drugs giant Bayer to accelerate the development and supply of its Covid-19 vaccine candidate.

CureVac Forms Covid-19 Vaccine Alliance With Bayer. The Stock Is Surging.

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, the two companies said on Thursday.

CureVac strikes COVID-19 vaccine alliance deal with Bayer

German biotech firm CureVac has agreed to an alliance with drugmaker Bayer to get global support in seeking approval for its experimental COVID-19 vaccine and for distribution, daily Bild reported.

CureVac strikes COVID-19 vaccine alliance deal with Bayer -Bild

LEVERKUSEN, Germany & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Leaps by Bayer and Senti Biosciences, Inc., a leading gene circuit company, today announced a USD 105 million Series B financing round. The financing was led by Leaps by Bayer, the impact investment arm of Bayer AG. Additional investors included Matrix Partners China, Mirae Asset Capital, Ridgeback Capital and Intel Capital as well as existing investors, including New Enterprise Associates (NEA), 8VC, Amgen Ventures and Lux Cap

Leaps by Bayer Leads USD 105 Million Series B Financing in Senti Bio to Develop Next-Generation Cell and Gene Therapies Using Advanced Gene Circuit Technology Platform

Veracyte

WHIPPANY, N.J. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Bayer and Veracyte (Nasdaq:VCYT) today announced a new collaboration to advance the Precision Oncology Patient Identification Program in thyroid cancer. Through the program, Bayer will offer testing with Veracyte's Afirma Xpression Atlas (XA) to identify underlying genomic drivers, including NTRK gene fusions, within patients' tumors. The program will focus on patients with advanced or metastatic thyroid cancer that is radioactive i

Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer and the humanitarian organization Direct Relief today announced a new grant program designed to help address financial and educational barriers to contraceptives, enabling women to make powerful decisions about their families and their futures with the help of their healthcare providers. Direct Relief has identified four health clinics that will be awarded $40,000 each to develop programs that expand access to contraceptives for underserved or underinsured

Bayer and Direct Relief Partnership Expands Access to Contraceptives with New Grant Initiative

WHIPPANY, N.J. & CHICAGO--(BUSINESS WIRE)--Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing assay, for a subset of patients with metastatic

News for Bayer AG Stock (BAYRY)